The European Tribune is a forum for thoughtful dialogue of European and international issues. You are invited to post comments and your own articles.
Please REGISTER to post.
HVTN 702 is part of a larger HIV vaccine research endeavor led by the Pox-Protein Public-Private Partnership, or P5 -- a diverse group of public and private organizations working to build on the RV144 trial. P5 members include NIAID, the Bill & Melinda Gates Foundation, and the South African Medical Research Council, which funded HVTN 702; the HIV Vaccine Trials Network (HVTN), headquartered at the Fred Hutchinson Cancer Research Center in Seattle, which conducted HVTN 702; Sanofi Pasteur and GSK, which provided study materials; and the U.S. Military HIV Research Program.
According to Balloux, the variant could have evolved during a "chronic infection of an immunocompromised person, possibly in an untreated HIV/AIDS patient"
by gmoke - Oct 1
by Frank Schnittger - Sep 24 2 comments
by Oui - Sep 19 19 comments
by Oui - Sep 13 35 comments
by Frank Schnittger - Sep 11 5 comments
by Cat - Sep 13 9 comments
by Frank Schnittger - Sep 2 2 comments
by Oui - Sep 3018 comments
by Oui - Sep 29
by Oui - Sep 28
by Oui - Sep 279 comments
by Oui - Sep 2618 comments
by Frank Schnittger - Sep 242 comments
by Oui - Sep 1919 comments
by gmoke - Sep 173 comments
by Oui - Sep 153 comments
by Oui - Sep 15
by Oui - Sep 1411 comments
by Oui - Sep 1335 comments
by Cat - Sep 139 comments
by Oui - Sep 127 comments
by Frank Schnittger - Sep 115 comments
by Oui - Sep 929 comments
by Oui - Sep 713 comments
by Oui - Sep 61 comment
by Frank Schnittger - Sep 22 comments